News & Updates

Genetic predisposition to major depressive disorder has the potential to increase the risk of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), peptic ulcer disease, and nonalcoholic fatty liver disease (NAFLD), according to the results of a Mendelian randomization study.

Modulation of gut microbiome using the SIM01 synbiotic formula significantly improves neuropsychiatric and gastrointestinal (GI) symptoms of long COVID, according to results of the randomized, triple-blind, placebo-controlled RECOVERY study conducted by researchers from the Chinese University of Hong Kong (CUHK).

The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.

The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.